Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Japan Should Invest More in Whole Genome Sequencing and Interpretation of Cancer-related Genomic Abnormalities: Dr Nakagawa of RIKEN
January 9, 2013
- BONAC Offers Solutions to Overcome Difficulties Faced in Development of Nucleic Acid Medicines: Managing Director Mizutani
January 9, 2013
- Nippon Kayaku Ups FY2012 Outlook for Pharma Biz, Anticancer Generics Brisk
January 8, 2013
- Abbott Japan’s Spin-Off AbbVie G.K. Starts Operations in January with CEO Winer
January 8, 2013
- “Appropriate Expressions” of Disease Awareness Ads Being Tested
January 7, 2013
- Sanofi K.K. Acquires DPP-4, SGLT-2 Inhibitors from Novartis, Chugai Aiming for Growth of Its Own Major Products for Diabetes through Synergism
January 7, 2013
- Lilly and BI in Long-term Collaboration; AZ and BMS Expanding Product Lineup
January 7, 2013
- Kowa Acquires 2 Major Products for “Post-Livalo” Era; How to Avoid Competition between Partners Holds Key in Comarketing
January 7, 2013
- Kyowa Kirin to Enhance Nephrology Lineup with DPP-4 Inhibitor; Companies Aiming to Capture Market through “2-Sword” Strategy
January 7, 2013
- Yoshindo, Ajinomoto Pharmaceuticals to Establish Joint Venture in Infusion and Dialysis Business
December 28, 2012
- Kissei Submits Application for Additional Indications for Combination Therapy of Glufast and DPP-4 Inhibitor or Biguanide
December 28, 2012
- Takeda Terminates Agreement with US Company on Anti-Obesity Drug Development
December 27, 2012
- Mitsubishi Chemical HD to Acquire Qualicaps
December 27, 2012
- Otsuka, Lundbeck File MAA for Abilify Once-Monthly Formulation with EMA
December 27, 2012
- Janssen Pharmaceutical Files for Additional Indication of Chronic Pain for OneDuro Patch
December 26, 2012
- Terumo Forms Alliance with AngioCare of China for Renal Denervation Catheter
December 26, 2012
- Takeda to Establish Global Customer Market Business Insights Department
December 26, 2012
- Takeda Voluntarily Recalls Ethical Version of Alinamin-F5 Injection
December 26, 2012
- Immunotherapeutic Cancer Drug Fails to Meet Primary Endpoint in PIII Study: Merck Serono
December 25, 2012
- Mortality Rate of Patients After Major Bleeds Significantly Lower with Dabigatran: BI
December 25, 2012
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…